The role of growth factors in the pathogenesis of diabetic retinopathy

Maria B. Grant, Aqeela Afzal, Polyxenie Spoerri, Hao Pan, Lynn C. Shaw, Robert N. Mames

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

Diabetic retinopathy (DR) is the most severe of several ocular complications of diabetes. The earliest clinical signs of DR are microaneurysms and haemorrhages. Later signs include dilated, tortuous irregular veins and retinal nonprofusion, leading to retinal ischaemia that ultimately results in neovascularisation. Diabetic macular oedema, which involves the breakdown of the blood-retinal barrier, also occurs and is responsible for a major part of vision loss, particularly in Type 2 diabetes. The pathogenesis of DR is very complex. Many biochemical mechanisms have been proposed as explanations for the development and progression of DR. Chronic hyperglycaemia leads to oxidative injury, microthrombi formation, cell adhesion molecule activation, leukostasis and cytokine activation. Next, ischaemia-mediated overexpression of growth factors and cytokines occurs. These factors include vascular endothelial growth factor, insulin-like growth factor-1, angiopoetin-1 and -2, stromal-derived factor-1, fibroblast growth factor-2 and tumour necrosis factor. Because of the complex interplay between these factors, targeting a single growth factor will be unlikely to result in therapeutic inhibition of angiogenesis. These growth factors no doubt act in synergy to mediate the steps of angiogenesis, including protease production, endothelial cell proliferation, migration and tube formation. This review attempts to provide an overview of perspectives regarding the pathogenesis of this disease. The focus, however, is on describing the unique features of selected relevant factors and how each growth factor may act in a synergistic manner with other factors. 2004

Original languageEnglish (US)
Pages (from-to)1275-1293
Number of pages19
JournalExpert Opinion on Investigational Drugs
Volume13
Issue number10
DOIs
StatePublished - Oct 2004
Externally publishedYes

Fingerprint

Diabetic Retinopathy
Intercellular Signaling Peptides and Proteins
Leukostasis
Ischemia
Blood-Retinal Barrier
Cytokines
Retinal Vein
Macular Edema
Cell Adhesion Molecules
Somatomedins
Fibroblast Growth Factor 2
Diabetes Complications
Hyperglycemia
Type 2 Diabetes Mellitus
Vascular Endothelial Growth Factor A
Cell Movement
Peptide Hydrolases
Endothelial Cells
Tumor Necrosis Factor-alpha
Cell Proliferation

Keywords

  • Angiogenesis
  • IGF
  • IGFBP
  • Integrins
  • Neovascularisation
  • Proliferative diabetic retinopathy
  • SDF
  • TNF
  • VEGF

ASJC Scopus subject areas

  • Pharmacology

Cite this

Grant, M. B., Afzal, A., Spoerri, P., Pan, H., Shaw, L. C., & Mames, R. N. (2004). The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opinion on Investigational Drugs, 13(10), 1275-1293. https://doi.org/10.1517/13543784.13.10.1275

The role of growth factors in the pathogenesis of diabetic retinopathy. / Grant, Maria B.; Afzal, Aqeela; Spoerri, Polyxenie; Pan, Hao; Shaw, Lynn C.; Mames, Robert N.

In: Expert Opinion on Investigational Drugs, Vol. 13, No. 10, 10.2004, p. 1275-1293.

Research output: Contribution to journalArticle

Grant, MB, Afzal, A, Spoerri, P, Pan, H, Shaw, LC & Mames, RN 2004, 'The role of growth factors in the pathogenesis of diabetic retinopathy', Expert Opinion on Investigational Drugs, vol. 13, no. 10, pp. 1275-1293. https://doi.org/10.1517/13543784.13.10.1275
Grant, Maria B. ; Afzal, Aqeela ; Spoerri, Polyxenie ; Pan, Hao ; Shaw, Lynn C. ; Mames, Robert N. / The role of growth factors in the pathogenesis of diabetic retinopathy. In: Expert Opinion on Investigational Drugs. 2004 ; Vol. 13, No. 10. pp. 1275-1293.
@article{7fe9adb0c09d4c399f40837e0259e6e3,
title = "The role of growth factors in the pathogenesis of diabetic retinopathy",
abstract = "Diabetic retinopathy (DR) is the most severe of several ocular complications of diabetes. The earliest clinical signs of DR are microaneurysms and haemorrhages. Later signs include dilated, tortuous irregular veins and retinal nonprofusion, leading to retinal ischaemia that ultimately results in neovascularisation. Diabetic macular oedema, which involves the breakdown of the blood-retinal barrier, also occurs and is responsible for a major part of vision loss, particularly in Type 2 diabetes. The pathogenesis of DR is very complex. Many biochemical mechanisms have been proposed as explanations for the development and progression of DR. Chronic hyperglycaemia leads to oxidative injury, microthrombi formation, cell adhesion molecule activation, leukostasis and cytokine activation. Next, ischaemia-mediated overexpression of growth factors and cytokines occurs. These factors include vascular endothelial growth factor, insulin-like growth factor-1, angiopoetin-1 and -2, stromal-derived factor-1, fibroblast growth factor-2 and tumour necrosis factor. Because of the complex interplay between these factors, targeting a single growth factor will be unlikely to result in therapeutic inhibition of angiogenesis. These growth factors no doubt act in synergy to mediate the steps of angiogenesis, including protease production, endothelial cell proliferation, migration and tube formation. This review attempts to provide an overview of perspectives regarding the pathogenesis of this disease. The focus, however, is on describing the unique features of selected relevant factors and how each growth factor may act in a synergistic manner with other factors. 2004",
keywords = "Angiogenesis, IGF, IGFBP, Integrins, Neovascularisation, Proliferative diabetic retinopathy, SDF, TNF, VEGF",
author = "Grant, {Maria B.} and Aqeela Afzal and Polyxenie Spoerri and Hao Pan and Shaw, {Lynn C.} and Mames, {Robert N.}",
year = "2004",
month = "10",
doi = "10.1517/13543784.13.10.1275",
language = "English (US)",
volume = "13",
pages = "1275--1293",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - The role of growth factors in the pathogenesis of diabetic retinopathy

AU - Grant, Maria B.

AU - Afzal, Aqeela

AU - Spoerri, Polyxenie

AU - Pan, Hao

AU - Shaw, Lynn C.

AU - Mames, Robert N.

PY - 2004/10

Y1 - 2004/10

N2 - Diabetic retinopathy (DR) is the most severe of several ocular complications of diabetes. The earliest clinical signs of DR are microaneurysms and haemorrhages. Later signs include dilated, tortuous irregular veins and retinal nonprofusion, leading to retinal ischaemia that ultimately results in neovascularisation. Diabetic macular oedema, which involves the breakdown of the blood-retinal barrier, also occurs and is responsible for a major part of vision loss, particularly in Type 2 diabetes. The pathogenesis of DR is very complex. Many biochemical mechanisms have been proposed as explanations for the development and progression of DR. Chronic hyperglycaemia leads to oxidative injury, microthrombi formation, cell adhesion molecule activation, leukostasis and cytokine activation. Next, ischaemia-mediated overexpression of growth factors and cytokines occurs. These factors include vascular endothelial growth factor, insulin-like growth factor-1, angiopoetin-1 and -2, stromal-derived factor-1, fibroblast growth factor-2 and tumour necrosis factor. Because of the complex interplay between these factors, targeting a single growth factor will be unlikely to result in therapeutic inhibition of angiogenesis. These growth factors no doubt act in synergy to mediate the steps of angiogenesis, including protease production, endothelial cell proliferation, migration and tube formation. This review attempts to provide an overview of perspectives regarding the pathogenesis of this disease. The focus, however, is on describing the unique features of selected relevant factors and how each growth factor may act in a synergistic manner with other factors. 2004

AB - Diabetic retinopathy (DR) is the most severe of several ocular complications of diabetes. The earliest clinical signs of DR are microaneurysms and haemorrhages. Later signs include dilated, tortuous irregular veins and retinal nonprofusion, leading to retinal ischaemia that ultimately results in neovascularisation. Diabetic macular oedema, which involves the breakdown of the blood-retinal barrier, also occurs and is responsible for a major part of vision loss, particularly in Type 2 diabetes. The pathogenesis of DR is very complex. Many biochemical mechanisms have been proposed as explanations for the development and progression of DR. Chronic hyperglycaemia leads to oxidative injury, microthrombi formation, cell adhesion molecule activation, leukostasis and cytokine activation. Next, ischaemia-mediated overexpression of growth factors and cytokines occurs. These factors include vascular endothelial growth factor, insulin-like growth factor-1, angiopoetin-1 and -2, stromal-derived factor-1, fibroblast growth factor-2 and tumour necrosis factor. Because of the complex interplay between these factors, targeting a single growth factor will be unlikely to result in therapeutic inhibition of angiogenesis. These growth factors no doubt act in synergy to mediate the steps of angiogenesis, including protease production, endothelial cell proliferation, migration and tube formation. This review attempts to provide an overview of perspectives regarding the pathogenesis of this disease. The focus, however, is on describing the unique features of selected relevant factors and how each growth factor may act in a synergistic manner with other factors. 2004

KW - Angiogenesis

KW - IGF

KW - IGFBP

KW - Integrins

KW - Neovascularisation

KW - Proliferative diabetic retinopathy

KW - SDF

KW - TNF

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=5444258548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5444258548&partnerID=8YFLogxK

U2 - 10.1517/13543784.13.10.1275

DO - 10.1517/13543784.13.10.1275

M3 - Article

C2 - 15461557

AN - SCOPUS:5444258548

VL - 13

SP - 1275

EP - 1293

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 10

ER -